Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPY072 in moderate to severe hidradenitis suppurativa
NCT07766005Phase 2Recruiting
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Sep 2026
- Primary completion
- Oct 2027
- Countries
- 2
01
Overview
A Phase 2 trial of SPY072 in hidradenitis suppurativa (HS), sponsored by Spyre Therapeutics, Inc.. Started Sep 2026; status: recruiting.
02
Drugs
SPY072
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07766005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07766005.